Meeting
2018 ASCO Annual Meeting
CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.
Authors
Nizar M. Tannir
The University of Texas MD Anderson Cancer Center, Houston, TX
Nizar M. Tannir , Robert J. Motzer , Neeraj Agarwal , Ping-Yu Liu , Samuel H. Whiting , Bridget O'Keeffe , Xuan Tran , Gayle P. Fiji , Bernard Escudier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03428217
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS4601)
DOI
10.1200/JCO.2018.36.15_suppl.TPS4601
Abstract #
TPS4601
Poster Bd #
419b
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma.
First Author: Nizar M. Tannir
Poster
2020 ASCO Virtual Scientific Program
INMUNOSUN-SOGUG trial: A prospective phase II study to assess the efficacy and safety of sunitinib as second-line (2L) treatment in patients (pts) with metastatic renal cell cancer (RCC) who received immunotherapy-based combination upfront.
First Author: Enrique Grande
Poster
2019 Genitourinary Cancers Symposium
CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.
First Author: Funda Meric-Bernstam
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase II study of neoadjuvant tislelizumab and axitinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma (accRCC).
First Author: Shun Zhang